Benda to enter India's $204M oncology market
Benda Pharmaceutical, a China-based pharmaceutical company producing traditional Chinese and conventional medicines, has announced that Gendicine, a recombinant human adenovirus vector p53 gene injection, for the treatment of cancer, has passed major milestones in its clinical trials in India and is expected to be approved for sale there in 2008.
This anticipated approval would mark Benda's entry into the $204.0 million Indian oncology drug market, and would make Gendicine available to treat cancer in the two most populous nations on the planet. The Indian market is just one of many in which Benda is seeking approval for its drug and represents the first step in the firm's progressive globalization plan for the product.
Leverages established distribution system through joint venture
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze